Point72 Asset Management
DRUG

Point72 Asset Management’s Bright Minds Biosciences DRUG Stock Holding History

Point72 Asset Management’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23M Buy
+327,416
New +$25.7M 0.03% 805
2025
Q4 		– Sell
-105,020
Closed -$6.37M – 3964
2025
Q3 		$6.37M Sell
105,020
-30,000
-22% -$1.16M 0.01% 977
2025
Q2 		$3.53M Hold
135,020
– – 0.01% 1089
2025
Q1 		$4.87M Sell
135,020
-169
-0.1% -$6.19K 0.01% 936
2024
Q4 		$4.87M Buy
+135,189
New +$4.76M 0.01% 953

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Point72 Asset Management's DRUG Position: Q2 2026 in Review

Point72 Asset Management opened a new position in Bright Minds Biosciences (DRUG) in Q2 2026: 327,416 shares worth $23M. The stake represents 0.03% of the portfolio and ranks #805 among its holdings. This is a return to the name: Point72 Asset Management previously reported a position in DRUG as recently as Q3 2025.

Point72 Asset Management first reported a position in DRUG in Q4 2024 and has held it in 5 quarters since. 100 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • Point72 Asset Management held 327,416 shares of Bright Minds Biosciences worth $23M as of Q2 2026.
  • Bright Minds Biosciences was a new Point72 Asset Management position in Q2 2026.
  • Bright Minds Biosciences made up 0.03% of Point72 Asset Management's portfolio in Q2 2026, its #805 holding.
  • Point72 Asset Management first reported a position in Bright Minds Biosciences in Q4 2024 and has held it in 5 quarters since.
  • 100 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.